

Sanofi Genzyme welcomes inquiry into allergic diseases in Australia

Sydney, Australia – 13 September 2019 – Sanofi Genzyme welcomes the Federal Government’s announcement of the House of Representatives Standing Committee on Health, Aged Care and Sport Inquiry into allergic diseases in Australia.

Allergic diseases are common in Australia and the prevalence is increasing¹. They are the fastest growing chronic diseases in Australia and include food, insect, and drug allergies, asthma, allergic rhinitis and atopic dermatitis.²

Allergic diseases are often misunderstood and underappreciated, and this inquiry will allow patients and their families to put a spotlight on the burden of living with allergic disease.

Sanofi Genzyme Australia and New Zealand Head of Medical, Paul King, said this announcement is positive news and is encouraging for atopic dermatitis patients and their families who experience the severity of the disease.

“There continues to be a high unmet medical need for patients with moderate-to-severe atopic dermatitis”.

“People living with this condition often experience disrupted sleep, anxiety and symptoms of depression along with their disease. These physical and psychological burdens can have devastating impacts on a patient’s quality of life”³.

“We look forward to seeing the inquiry findings and most importantly how they may improve access to therapies and better healthcare outcomes.”

About Sanofi Australia

Sanofi is dedicated to supporting people through their health challenges.

¹ ASCIA 2019, What is Allergy. Information for patients, consumers and carers

² Jo A Douglass, MJA, 2006 Diagnosis, treatment and prevention of allergic disease: the basics

³ Eichenfield et al, AAD 2014, Guidelines of Care for Atopic Dermatitis

². Simpson EL et al. N Engl J Med 2016;375:2335–2348.

We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide self-care solutions to better manage personal wellbeing and provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. While our local corporate headquarters are in Sydney we also have offices, state-of-the-art laboratories and a world-class manufacturing facility in Brisbane, and offices across Auckland, Melbourne, Adelaide and Perth.

Sanofi, Empowering Life

**Sanofi Australia
Media Relations Contact**

Amy O'Hara
Communications Manager
Tel.: 0417 861 984
Amy.O-hara@sanofi.com

Rebekah Cassidy
Head of Communications
Tel: 0402 397 498
Rebekah.Cassidy@sanofi.com

sanofi-aventis australia pty ltd trading as Sanofi, ABN 31 008 558 807, Talavera Corporate Centre,
Building D, 12–24 Talavera Road, Macquarie Park, NSW 2113
Date of preparation: September 2019. SAANZ.DUP.19.09.0432